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Abstract
Cancer therapy is a dynamically evolving field. Chemotherapy and biologic agents
impact the magnitude and duration of immunosuppression in the already-immuno-
compromised cancer hosts who are then susceptible to a broad spectrum of infectious
complications ranging from mild opportunistic infections to severe, fatal neutropenic
sepsis. Numerous bacterial, fungal, and viral organisms have been implicated dictating
varied preventative  approaches.  Rapid assessment  and risk  stratification of  febrile
patients  identify  individuals  requiring  hospital  admission.  Timely  delivery  of
antimicrobials reduces the risk of complications and death. Herein, we summarize the
current “state of art” in the management of infection in the cancer patient. We detail the
advances in antibacterial and antifungal therapy.
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1. Introduction
Cancer patients are at a risk for development of severe infections. Predisposing factors include
severe  neutropenia,  impaired  neutrophil  function,  and  B-cell,  T-cell,  or  NK-cell  defects.
Patients  with  chronic  lymphocytic  leukemia  often  have  hypogammaglobulinemia  which
increases  susceptibility  to  encapsulated  bacteria.  Patients  with  advanced  solid  tumors
including head and neck cancer, lung cancer, gastrointestinal malignancy, and pancreatic
cancer are commonly malnourished. Malnutrition impairs immune function and increases the
susceptibility to infection. Chemotherapy, biological agents, and high-dose steroids may also
cause significant immunosuppression, thereby increasing the risk for infection. In the United
States,  approximately 60,000 patients  are admitted due to neutropenia,  annually.  One in
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fourteen of these patients dies secondary to sepsis-related complications [1]. The estimated
daily cost of hospitalization is $2,000–$3,000 [2]. Advances in infection control and antimicro-
bial  stewardship  are  therefore  important  to  diminish  the  impact  of  infections  in  these
immunocompromised hosts.
2. Cancer therapy–related infections
Most single chemotherapeutic agents used for the treatment of solid tumors do not cause
prolonged neutropenia and are therefore associated with a low risk for bacterial infections.
Additionally, they do not cause significant suppression of T-cell function leading to clinically
relevant viral reactivation. On the other hand, induction and consolidation chemotherapy for
acute leukemia may result in severe, prolonged neutropenia, thereby not only increasing the
risk of bacterial and fungal infections but also predisposing to herpes simplex virus (HSV)
reactivation [3].
Epidermal growth factor receptor (EGFR) inhibitors are commonly used in the treatment of
solid tumors. Cetuximab is a chimeric murine-human IgG1 monoclonal antibody that is used
in the treatment of head and neck cancer and advanced colorectal cancer. Panitumumab is a
fully human IgG2 monoclonal antibody used in the treatment of advanced colorectal cancer.
Erlotinib and gefitinib are used in the treatment of lung adenocarcinoma. These EGFR
inhibitors may be associated with acneiform eruptions and paronychia. Severe skin toxicities
complicated by infection, abscess, and sepsis have also been reported. Trastuzumab and
pertuzumab are anti-HER2 monoclonal antibodies used in the treatment of breast cancer. In a
meta-analysis of 13 randomized studies of breast cancer patients (N = 10,094), treatment with
trastuzumab was associated with 8.5 % (95 % CI 4.5–15.4 %) incidence of high-grade infection
and 12.0 % (95 % CI 8.1–17.4 %) incidence of febrile neutropenia in the absence of high-grade
neutropenia or leukopenia [4].
Mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus) is used in
the treatment of advanced renal cell carcinoma. Severe lymphopenia, neutropenia, and sepsis
have been reported. Immunosuppression with these agents may increase the risk of oppor-
tunistic infections including Pneumocystis jiroveci pneumonia (PJP). In a meta-analysis of ten
randomized trials of cancer patients (N = 3,535), everolimus and temsirolimus were associated
with a 21 % (95 % CI 15.0–28.9 %) risk of high-grade infections [5].
Vascular endothelial growth factor receptor/tyrosine kinase inhibitors (VEGFR-TKIs) block
angiogenesis by inhibiting VEGF and other growth factors. They are used in the treatment of
a variety of tumors including chronic myelogenous leukemia (imatinib, dasatinib, nilotinib),
renal cancer (sunitinib, sorafenib, pazopanib, and axitinib), hepatocellular carcinoma (sorafe-
nib), colorectal cancer (regorafenib), thyroid cancer (sorafenib, vandetanib), and sarcoma
(cediranib). In a meta-analysis of 27 randomized trials (N = 16,488), VEGFR-TKIs significantly
increased the risk of developing severe (1.69-fold) and fatal infectious events (1.78-fold) in
cancer patients [6].
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Monoclonal antibodies that target B lymphocytes cause significant cellular immunosup-
pression predisposing to bacterial, fungal, and viral infections. Reactivation of hepatitis B
virus (HBV) is more common compared to other viruses such as herpes simplex virus
(HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV)
[7]. These agents should not be administered to patients with active infection. Anti-CD20-
directed monoclonal antibodies (rituximab, ofatumumab, and obinutuzumab) are used in
the treatment of lymphoproliferative disorders. Their use is associated with HBV reactiva-
tion resulting in fulminant hepatitis, hepatic failure, and death [8, 9]. Anti-CD30-directed
monoclonal antibody (brentuximab vedotin) is used in the management of relapsed
Hodgkin’s lymphoma and anaplastic large-cell lymphoma. Its use is associated with pro-
longed severe neutropenia and neutropenic fever. Cases of progressive multifocal leu-
koencephalopathy (PML) and death due to JC virus infection have also been reported
[10]. Anti-CD38-directed monoclonal antibody (daratumumab) is used in the management
of refractory multiple myeloma. Its use is associated with myelosuppression. Herpes zos-
ter occurs in 3 % of patients. Antiviral prophylaxis to prevent herpes zoster reactivation
should be initiated within one week of starting daratumumab and continued for three
months following the last dose [11]. Anti-CD52-directed monoclonal antibody (alemtuzu-
mab) is used for treatment of chronic lymphocytic leukemia. It induces severe and pro-
longed lymphopenia and increases the risk of serious and potentially fatal bacterial, viral,
fungal, and protozoan infections. Prophylactic medications against PJP and herpes virus
infection during treatment and for at least 2 months following last dose or until CD4+
counts are ≥200 cells/μL are recommended. Close monitoring for CMV reactivation is also
recommended [12].
Signaling lymphocyte activation molecule family 7 (SLAMF7) is present on myeloma cells and
natural killer cells. Anti-SLAMF7-directed monoclonal antibody (elotuzumab) is administered
in combination with lenalidomide and dexamethasone for refractory myeloma. Bone marrow
suppression and increased risk of opportunistic, fungal, and herpes zoster infection have been
reported [13].
Janus kinase (JAK) 1/2 inhibitor, ruxolitinib, is used for the treatment of polycythemia vera
and myelofibrosis. Its use is associated with impairment of dendritic cell and T-cell function
and reduction in cytokines resulting in the development of serious bacterial, fungal, and viral
infections. Opportunistic infections reported include HBV reactivation, disseminated tuber-
culosis, Cryptococcus pneumonia, toxoplasmosis retinitis, and PML [14, 15].
Checkpoint inhibitors target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and
programmed cell death-1 (PD-1) receptor. Anti-CTLA-4 antibody (ipilimumab) is used in the
treatment of melanoma. Anti-PD-1 antibodies (nivolumab and pembrolizumab) are used in
the management of melanoma and lung cancer. Checkpoint inhibition is associated with
immune-mediated adverse events including pneumonitis, colitis, hepatitis, nephritis, derma-
titis, and endocrinopathies. High-dose glucocorticoids are used in the management of grade
2 or greater immune-related toxicities, which increase the risk for development of opportun-
istic infections.
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3. Role of antimicrobial prophylaxis in the prevention of cancer-related
infections
Infection risk in patients with cancer depends on several factors including age more than 65
years, tumor burden (size and number of lesions), regimen and intensity of cytotoxic chemo-
therapy, duration of neutropenia, degree of mucositis, and associated comorbidities. Intense
cytotoxic chemotherapy causes prolonged neutropenia which impairs the inflammatory
response and predisposes the individual to serious infection(Figure 1).
Figure 1. National Comprehensive Cancer Network (NCCN) criteria for risk of infection in patients undergoing che-
motherapy [16].
Neutropenia is a major risk factor for the development of infections. Neutropenic fever is more
common after chemotherapy for hematologic malignancies than solid tumors. Preventive
measures against infections involve antimicrobial prophylaxis for patients receiving chemo-
therapy regimens associated with greater than or equal to twenty percent risk for fever and
neutropenia.
3.1. Antibacterial prophylaxis during neutropenia
Patients receiving combination or dose-intensive chemotherapy are at increased risk for
prolonged neutropenia [absolute neutrophil count (ANC) < 1,000/μL lasting more than 7 days]
and bacterial infections. Gram-negative bacilli are associated with life-threatening infections.
In a meta-analysis of neutropenic patients (18 trials, N = 1,408) with solid tumors and hema-
tological malignancies, fluoroquinolone prophylaxis (ciprofloxacin, norfloxacin, enoxacin, and
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ofloxacin) significantly lowered the incidence of gram-negative infections by 80 % (RR, 0.21;
95 % CI 0.12–0.37) when compared with placebo and by 70 % when compared with trimetho-
prim-sulfamethoxazole (TMP-SMX). Quinolone prophylaxis did not alter the incidence of
gram-positive bacterial and fungal infections or infection-related deaths [17]. In another meta-
analysis of afebrile neutropenic patients (109 trials, N = 13,579) with hematologic malignancies,
antibiotic prophylaxis significantly decreased all-cause mortality (RR 0.66, 95 % CI 0.55–0.79)
and infection-related mortality (RR 0.61, 95 % CI 0.48–0.77) compared to placebo or no
intervention. Quinolone prophylaxis was associated with the most significant reduction in
mortality [18]. Ciprofloxacin is more potent than levofloxacin against gram-negative bacteria.
Nevertheless, levofloxacin with wider activity against gram-positive cocci may benefit as a
prophylactic agent for mucositis-associated infections.
Levofloxacin prophylaxis in high-risk patients with anticipated prolonged neutropenia
reduces clinically significant bacterial infections including gram-negative bacteremia [19].
Prophylaxis in low-risk patients with anticipated short-duration neutropenia decreases fever
and hospitalization for febrile neutropenia, but not infection-related mortality [20]. Fluoro-
quinolone use may be associated with hypersensitivity reactions, prolonged QTc interval,
tendon rupture, peripheral neuropathy, seizures, Clostridium difficile diarrhea, Streptococcus
viridans bacteremia, and methicillin-resistant Staphylococcus aureus (MRSA) infection [21–23].
The National Comprehensive Cancer Network (NCCN) guidelines panel recommends the use
of fluoroquinolone prophylaxis (levofloxacin) for patients with anticipated prolonged neutro-
penia. Antibacterial prophylaxis is not recommended for anticipated short-duration neutro-
penia due to the risk of emergence of quinolone-resistant bacteria [24].
3.2. Antifungal prophylaxis
Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and
allogeneic hematopoietic stem cell transplant (HSCT) recipients are at increased risk for life-
threatening infections with yeasts or molds. Candida and Aspergillus species are the most
common pathogens. Amphotericin B (AMB) has activity against both Candida spp. and
Aspergillus spp. but is too toxic for antifungal prophylaxis.
Studies supporting antifungal prophylaxis in patients undergoing induction chemotherapy
for AML have shown that fluconazole is superior to placebo in preventing invasive candidia-
sis [25] and is as effective as amphotericin B [26]. However, fluconazole lacks activity against
molds. Itraconazole has activity against both Candida and Aspergillus species. It significantly
reduces invasive fungal disease (IFD) compared to fluconazole at the cost of greater toxicity
[27–29]. Voriconazole is active against a wider range of fungi including Candida spp., Aspergillus
spp., Scedosporium spp., and Fusarium spp. [30]. Nevertheless, data supporting voriconazole
prophylaxis in the non-transplant AML population is limited. Posaconazole has broader
antifungal coverage including Candida spp., Aspergillus spp., Scedosporium spp., Fusarium spp.,
and Mucorales. It is the only agent that has demonstrated survival benefit in prophylaxis against
mycosis during AML induction therapy [31]. Azoles (itraconazole, voriconazole, and posaco-
nazole) inhibit cytochrome P450 3A4 isoenzyme and may decrease the clearance of antineo-
plastic agent vincristine. Caspofungin is active against both Candida and Aspergillus spp. It has
Infections in Cancer Patients
http://dx.doi.org/10.5772/64372
121
similar efficacy as itraconazole and is better tolerated [32]. It may therefore be a reasonable
substitute for antifungal prophylaxis in patients who are unable to tolerate oral posaconazole.
Antifungal prophylaxis in patients undergoing HSCT is more complex due to concerns for
poor oral absorption due to mucositis and drug interactions with antineoplastic and immu-
nosuppressive medications. Fluconazole decreases invasive candidiasis and IFD-related
mortality. Itraconazole has superior efficacy than fluconazole in prevention of IFD. Coadmi-
nistration of itraconazole with antineoplastic conditioning regimens containing cyclophos-
phamide is associated with increased incidence of renal and hepatic toxicities. Voriconazole is
as effective as itraconazole and is better tolerated [33]. Micafungin is as efficacious as itraco-
nazole with less toxicity [34]. In patients with GVHD requiring immunosuppressive therapy,
posaconazole has demonstrated improvement in IFD-related mortality (1 % vs. 4 %, p = .046)
compared to fluconazole [35, 36] (Figure 2).
Figure 2. Primary antifungal prophylaxis in patients with hematologic disorders. HSCT, hematopoietic stem cell trans-
plant; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; GVHD, graft-versus-host disease.
3.3. Anti-pneumocystis prophylaxis
P. jiroveci pneumonia (PJP) is a potentially life-threatening infection that may occur in immu-
nocompromised individuals with acute lymphocytic leukemia (ALL) and recipients of
allogeneic HSCT and alemtuzumab therapy. Patients receiving purine analog therapy,
temozolomide in conjunction with radiation therapy, and high-dose glucocorticoids (equiva-
lent to ≥20 mg of prednisone daily for 4 or more weeks) may also be at risk.
In patients with AML or solid organ transplantation, prophylaxis with TMP/SMX compared
to no treatment or treatment with fluoroquinolones reduced the incidence of PJP infections by
85 % (RR 0.15, 95 % CI 0.04–0.62; ten trials, 1,000 patients) and PJP-related mortality by 83 %
(RR 0.17, 95 % CI 0.03–0.94; nine trials, 886 patients). Reduction in all-cause mortality was not
observed. There was also no difference between once daily vs. thrice weekly TMP/SMX [37].
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TMP/SMX is superior to dapsone and pentamidine in allogeneic HSCT recipients [38, 39]. PJP
prophylaxis is administered for six months in allogeneic HSCT recipients and longer in
patients with GVHD. ALL patients should receive prophylaxis till completion of
immunosuppressive therapy. For those receiving alemtuzumab, anti-PJP prophylaxis is
continued for a minimum of 2 months beyond alemtuzumab therapy or when the CD4+ cell
count is above 200 cells/μL [16].
3.4. Antiviral prophylaxis
Most cancer patients are at low risk of contracting viral infections. Immunosuppression may
however predispose them to respiratory tract viral infections. Reactivation of HSV, VZV, and
HBV is more likely to occur during intensive chemotherapy. EBV and CMV occur in the setting
of allogeneic HSCT. The risk of viral infection increases with the intensity and duration of T-
cell suppression. The extent of neutropenia is less important.
3.4.1. Influenza virus
Inactivated influenza vaccine is administered annually to patients undergoing chemotherapy
[40]. Patients receiving induction or consolidation therapy for AML or those who have received
anti-B-cell antibody within the last six months are excluded. Vaccination should be adminis-
tered at least two weeks prior to receiving immunosuppressive therapy. Patients should be
considered unprotected if they were vaccinated less than 2 weeks before start of immunosup-
pressive therapy. These patients should be revaccinated at least three months after the cytotoxic
therapy is discontinued [41]. Acute leukemics should be vaccinated after completion of
chemotherapy. Patients with ALL should receive the vaccine during the maintenance phase of
their therapy [42].
3.4.2. Hepatitis B virus (HBV)
Reactivation of latent HBV occurs in patients with leukemia (ALL, AML, and chronic lym-
phocytic leukemia (CLL)), lymphoma, myeloma, and breast cancer, transplant recipients, or
patients receiving high-dose steroids, anti-CD 20 antibodies, alemtuzumab, or purine ana-
logs. Screening tests include hepatitis B surface antigen (HBsAg), hepatitis B core antibody
(anti-HBc), and HBV DNA. Patients who are HBsAg positive/anti-HBc positive or HBsAg
negative/anti-HBc positive are at risk for reactivation. Antiviral therapy should be initiated
in patients with HBsAg-positive/anti-HBc-positive serology either prior to or concurrent
with cytotoxic therapy. HBsAg-negative/anti-HBc-positive patients may be monitored for
reactivation with HBV DNA and Alanine Transferase (ALT) levels and antivirals initiated
at reactivation. Evidence of reactivation includes change in the HBV DNA from undetecta-
ble to detectable, or ≥1 log rise in HBV DNA level above baseline, or seroconversion from
negative to positive HBsAg status. ALT should be monitored to assess hepatic function in
the setting of HBV reactivation [43]. HBV DNA is monitored monthly during cytotoxic
therapy and then every 3 months after completion of therapy. Antiviral therapy should be
continued for 6 months after completion of cytotoxic therapy and for longer than 12
months in patients treated with anti-CD 20 monoclonal antibodies. HBV prophylaxis re-
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sults in 87 % relative risk reduction of reactivation [43]. It also prevents fulminant hepatitis
[44]. Entecavir is more effective than lamivudine and is associated with lower incidence of
viral resistance and hepatitis [9]. Allogeneic HSCT candidates with evidence of active HBV
infection should receive antiviral therapy for three to six months prior to initiation of con-
ditioning [45].
3.4.3. Herpes simplex virus (HSV)
Reactivation and infection with HSV occur in patients undergoing induction therapy for acute
leukemia and HSCT recipients. Prolonged neutropenia and mucositis are major predisposing
factors. The risk of HSV reactivation is highest in the first 30 days following allogeneic
transplant. Screening tests include HSV-1 and HSV-2 IgG antibodies. In a meta-analysis of nine
randomized trials of HSCT recipients, acyclovir prophylaxis reduced HSV infection (RR 0.19,
95 % CI 0.11–0.31) without impacting overall mortality [46]. Antiviral prophylaxis with
acyclovir or valacyclovir is therefore recommended in HSV-seropositive patients. The antiviral
agent is administered with the initiation of the conditioning regimen and is continued till either
engraftment occurs or the mucositis has resolved. Patients with chronic lymphocytic leukemia
(CLL) receiving alemtuzumab therapy are also at risk for HSV infection. Antiviral prophylaxis
is recommended for 2 months beyond alemtuzumab therapy or when the CD4+ cell count is
above 200 cells/μL [47].
3.4.4. Varicella zoster virus (VZV)
Reactivation of VZV occurs in seropositive HSCT recipients. Screening test includes VZV IgG
antibody. Antiviral prophylaxis with acyclovir or valacyclovir for one year post transplant
significantly reduces reactivation compared to no therapy (9 % vs. 25 %, p < 0.001) [48]. Patients
receiving T-cell-depleting agents (proteasome inhibitors, purine analogs, and predni-
sone ≥ 1 mg/kg/day) are also at risk for VZV infection. Antiviral prophylaxis is continued until
the immunosuppressive therapy is completed [49]. Recommendations for CLL patients
receiving alemtuzumab include continuing VZV prophylaxis for 2 months beyond completion
of treatment or when the CD4+ cell count is above 200 cells/μL.
3.4.5. Cytomegalovirus (CMV)
Reactivation and infection with CMV occur in allogeneic hematopoietic transplant recipients
and patients receiving alemtuzumab treatment [50]. Screening test includes weekly quantita-
tive CMV testing (CMV DNA by polymerase chain reaction (PCR) or CMV pp65 antigen from
peripheral blood leukocytes). CMV blood testing is done for at least six months after allogeneic
HSCT. Patient receiving alemtuzumab therapy should undergo surveillance during treatment
and for at least 2 months after completion of treatment. Preemptive therapy for patients with
CMV viremia is recommended rather than administering toxic antiviral prophylaxis. Treat-
ment is continued for 2 weeks or until CMV viremia is no longer detectable. First-line therapy
includes intravenous ganciclovir or oral valganciclovir. Ganciclovir is associated with bone
marrow suppression. Second-line option foscarnet is nephrotoxic. Both acyclovir and valacy-
clovir are less toxic and also less active than ganciclovir.
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4. Management of febrile neutropenia
4.1. Definitions
Fever is defined as a single oral temperature of ≥38.3 °C (101 °F) or a temperature of ≥38.0 °C
(100.4 °F) for 1 h or longer [24]. Neutropenia is defined as an absolute neutrophil count (ANC)
of <1,000 cells/μL. Severe neutropenia is defined as an ANC of <500 cells/μL. Profound
neutropenia is defined as an ANC of <100 cells/μL. Prolonged profound neutropenia (lasting
>7 days) is likely to occur in patients undergoing induction chemotherapy for acute leukemia
or after allogeneic HSCT. Functional neutropenia occurs in patients with hematologic malig-
nancy whose circulating neutrophils have impaired phagocytosis. These patients are at risk of
infection despite “normal” neutrophil counts [51].
4.2. Initial assessment and investigations
Febrile neutropenia is a medical emergency requiring immediate evaluation and administra-
tion of empiric broad-spectrum antibiotics within an hour of presentation [24]. The initial
assessment focuses on not only determining the probable site of infection but also the patient’s
risk of developing serious complications and the need for vigorous resuscitation. Relevant
historical information should include the chemotherapy regimen, number of chemotherapy
cycles, days since receiving anticancer treatment, concomitant use of biologic agents and
steroids, growth factor support, prophylactic antimicrobials, recent surgery or radiation
therapy, prior infections, HIV status, and other comorbid illnesses. Laboratory evaluation
should include complete blood count with differential, renal, and hepatic function tests and
cultures from all potential sites including sputum, urine, stool, skin, and mucosal ulcers as
clinically relevant. At least two sets of blood cultures from peripheral veins or one set each
from a peripheral vein and a central venous catheter should be drawn. Chest radiographs
should be evaluated in patients with signs or symptoms of lower respiratory tract infection.
4.3. Risk stratification
Patients with febrile neutropenia are risk stratified into high- or low-risk groups based on the
probability of development of serious infection-related complications.
4.3.1. The Talcott model
Patients are assigned to one of four Talcott model risk groups in the first 24 h of presentation.
In the prospective validation study of this model (N = 444), medical complications developed
in 5 % group IV patients compared to 34 % in combined groups I–III (p < .000001). There were
no deaths in group IV patients compared to 10 % deaths in combined groups I–III. Medical
complications included hypotension, tachyarrhythmias, congestive heart failure, respiratory
failure, serious bleeding, altered mental status, new focal neurologic changes, and intensive
care admission [52] (Figure 3).
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Figure 3. The Talcott model.
4.3.2. The MASCC risk index
The Multinational Association for Supportive Care in Cancer (MASCC) risk index uses
weighted scores based on disease burden, clinical instability, age, and comorbid conditions.
The maximum theoretical MASCC score is 26. Low-risk patients have a MASCC score ≥21 and
mortality as low as 3 %. High-risk patients with MASCC score <15 have a mortality as high as
36 %. The MASCC rule does not consider the duration of anticipated neutropenia as a criteria
for risk stratification [53]. Both Talcott model and MASCC index score are used to identify low-
risk febrile neutropenic patients who are suitable for outpatient management.
4.3.3. The NCCN model [16]
The NCCN guidelines panel considers high-risk febrile neutropenic patients as those with
MASCC scores of less than 21. The panel further recommends that patients with prolonged
profound neutropenia should be considered high risk, regardless of the MASCC risk index
score. Other factors stratifying patients as high risk include those noted in Figure 4. These high-
risk febrile neutropenic patients require hospital admission and parenteral therapy (Figure 5).
Figure 4. The MASCC risk index score.
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Figure 5. High-risk factors in febrile neutropenic patients.
4.4. Outpatient therapy for low-risk patients
Febrile neutropenic patients with MASCC scores ≥ 21 or in Talcott group 4 are at low risk for
infection-related complications provided they do not have active comorbidities or organ
dysfunction. These patients can be managed safely as outpatients if they live close to a medical
facility, agree to frequent clinic visits, and have 24-h caregiver support at home with easy access
to telephone and transportation. Low-risk patients should receive initial doses of empirical
antibacterial therapy within an hour of triage. They should then undergo a brief period of
observation (at least 4 h) in a medical facility to determine the suitability for outpatient
management or the need for hospitalization [51].
The majority of febrile neutropenic episodes in patients receiving chemotherapy for solid
tumors are low risk. Bacterial infections are the presumed culprits for unexplained fever.
Fungal infections are uncommon, and reactivation of viruses is rare. In a cohort of low-risk
febrile neutropenic patients (N = 757), unexplained febrile episodes were predominant (58 %),
followed by equal frequency (21 %) of both clinically significant and microbiologically
documented infections. The most common clinical sites of infection were the upper respiratory
tract and skin. Among microbiologically documented infections, monomicrobial gram-
positive infections accounted for 49 % (coagulase-negative staphylococci most frequent)
followed by monomicrobial gram-negative infections (36 %, Escherichia coli predominant) and
polymicrobial infections (15 %) [54].
Two randomized control trials (RCTs) of low-risk febrile neutropenic inpatients reported
similar efficacy of oral ciprofloxacin plus amoxicillin/clavulanate vs. an IV regimen (ceftazi-
dime or ceftriaxone plus amikacin) [55, 56]. Ciprofloxacin monotherapy provides suboptimal
coverage for gram-positive organisms including viridans group streptococci [57]. Levofloxacin
is more active against gram-positive bacteria but less active than ciprofloxacin against
Pseudomonas [58, 59]. A randomized trial (N = 333) reported similar efficacy (80 % vs. 82 %) of
oral moxifloxacin compared to oral ciprofloxacin plus amoxicillin/clavulanate. Neurologic
events were more common with moxifloxacin, and diarrhea was more common with the
combination therapy [60].
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Antibacterial therapy in low-risk patients with negative blood cultures is continued for at least
two afebrile days after ANC recovery to ≥500 cells/μL or for five to seven days in the absence
of myeloid reconstitution [61]. A meta-analysis of RCTs of low-risk febrile neutropenic patients
reported that outpatient oral and parenteral antibiotics had similar efficacy (RR 0.93). The site
of care (outpatient vs. inpatient) was not significantly associated with treatment failure (RR
0.81) [62]. The rate of hospital admission in patients receiving outpatient empiric therapy is in
the range of 3–10 %.
The American Society of Clinical Oncology (ASCO) panel recommends empiric oral fluoro-
quinolone (ciprofloxacin or levofloxacin) plus amoxicillin/clavulanate for low-risk febrile
neutropenic patients. Ciprofloxacin plus clindamycin is an alternative for penicillin-allergic
patients [24, 51]. The NCCN panel recommends moxifloxacin monotherapy for patients who
may not require Pseudomonas coverage. However, patients who have received fluoroquinolone
prophylaxis before fever developed are at increased risk for infection with antibiotic-resistant
strains including MRSA, vancomycin-resistant Enterococcus (VRE), and ESBL-producing gram-
negative bacteria. These patients therefore require hospital admission and initial management
with broad-spectrum parenteral antibiotics [24] (Figure 6).
Figure 6. Management of low-risk febrile neutropenia.
4.5. Initial empiric antibacterial therapy for high-risk patients
Fever through periods of prolonged profound neutropenia during induction chemotherapy
for acute leukemia or pre-engraftment phase of allogeneic HSCT may be due to serious or life-
threatening infections. Febrile neutropenic patients with severe comorbidities, hepatic or renal
dysfunction, or MASCC scores < 21 or in Talcott groups 1–3 are also at a high risk for infection-
related complications. These patients should receive emergent evaluation, prompt resuscita-
tion, and timely administration of broad-spectrum parenteral antibiotics to avoid progression
to a sepsis syndrome and possibly death. A retrospective study of patients with severe sepsis
reported decreased overall mortality (19.5 % vs. 33.2 %; p = .02) in patients who received
antibacterial therapy within 1 h of presentation as opposed to latter [63].
The selection of initial antibacterial agent for high-risk febrile neutropenic patients is guided
by clinical stability, recent antimicrobial use, medication allergy, potential site of infection, and
susceptibility patterns of institutional pathogens. Empiric antibiotic regimens should have a
broad spectrum (gram-positive and gram-negative coverage), bactericidal activity, antipseu-
domonal activity, and minimal toxicity. Current guidelines recommend initial monotherapy
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with antipseudomonal beta-lactam agent, such as cefepime, meropenem, imipenem-cilastatin,
or piperacillin-tazobactam [16, 24]. None of these agents is superior in the empiric treatment
of febrile neutropenia. However, ceftazidime monotherapy is avoided due to limited activity
against viridans group streptococci and rising resistance rates among gram-negative bacteria
[64].
Combination therapy is not superior to empiric monotherapy but may be associated with more
adverse effects. Aminoglycoside plus antipseudomonal agent may be considered for suspected
gram-negative bacteremia or sepsis syndrome or if the institution has high levels of gram-
negative-resistant bacteria [65–67].
Empiric vancomycin therapy is not associated with a benefit in mortality. Nevertheless, there
is concern regarding emergence of vancomycin-resistant Enterococcus (VRE) and S. aureus and
increased incidence of hepatic and renal toxicity [68–71]. Current guidelines do not support
its use as a routine component of the initial regimen. However, its empiric use is appropriate
for suspected vascular catheter-related infection (CRI), gram-positive bacteremia, cellulitis,
severe mucositis, hypotension or septic shock, pneumonia, and known colonization with
MRSA or drug-resistant Streptococcus pneumoniae [72–75]. Vancomycin is usually discontinued
after 48 h if cultures fail to grow resistant gram-positive organisms. In a randomized trial of
febrile neutropenic patients with proven or suspected gram-positive infection (N = 611),
linezolid demonstrated similar efficacy and safety when compared to vancomycin [76].
Linezolid is therefore an alternative for vancomycin-intolerant patients and vancomycin-
resistant gram-positive pathogens. Myelosuppression may limit its use in patients with
compromised bone marrow function.
Neutropenic sepsis is a major cause of mortality. Diagnostic criteria include altered mental
status, systolic hypotension of ≤100 mm Hg, and tachypnea of >22 breaths/min. These patients
should receive aggressive resuscitation and monitoring in an intensive care unit. Patients in
septic shock require vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mm Hg
despite adequate fluid resuscitation and have a lactate level >2 mmol/L. Stress-dose steroids
(50 mg hydrocortisone every six hours for 5–7 days) may benefit those with ongoing hypo-
tension (systolic blood pressure <90 mm Hg for more than 1 h) refractory to fluid resuscitation
and vasopressor support [77]. RCTs of patients with severe sepsis demonstrated that high-dose
steroids (>300 mg hydrocortisone per day) increased overall mortality and the risk of secon-
dary infections [78–81]. The initial empiric antimicrobial regimen should include a broad-
spectrum beta-lactam plus aminoglycoside plus vancomycin. In addition, antifungal agents
such as fluconazole or an echinocandin may be strongly considered.
The empiric broad-spectrum antibacterial should be continued until the patient is afebrile for
at least 2 days and the ANC is ≥500 cells/μL on at least one occasion but is showing a consistent
increasing trend. Documented infections should be managed with appropriate antimicrobials
based on blood culture and susceptibility results. High-risk patients with persistent unex-
plained fever despite 3–5 days of antibacterial therapy should undergo assessment for
undiagnosed fungal infection. Empiric coverage for Candida and/or for molds should also be
considered (Figure 7).
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Figure 7. Management of high-risk febrile neutropenia.
4.6. Empiric antifungal therapy
Persistent fever refers to an episode of fever during neutropenia that does not resolve after 4
days of broad-spectrum antibacterial agents. Recurrent fever refers to a new episode of fever
during neutropenia that occurs >2 days after resolution of a first fever while continuing broad-
spectrum antibacterial therapy. Patients with prolonged neutropenia with persistent or
recurrent fever are at increased risk for life-threatening infections with yeasts or molds. Early
detection of these invasive fungal diseases (IFDs) is challenging because of limited sensitivity
and specificity of clinical presentation and investigative modalities. As an example, the mere
isolation of Candida spp. from sputum, urine, or stool samples ascertains colonization only and
is not indicative of invasive infection requiring treatment [82].
Definitive diagnosis of IFD requires histological evidence of deep tissue invasion or positive
culture from normally sterile sites. Whereas histopathology has the ability to make organism-
specific diagnoses in only a few cases, the results of fungal cultures may not be available in a
timely fashion for clinical decisions. Furthermore, repeated biopsies and microbiologic
samplings may be difficult to obtain in critically ill neutropenic patients. Although molecular
diagnostics have the potential for increased sensitivity and a rapid turnaround time, it lacks
the ability to differentiate invasive infection from colonization or contamination. The detection
of fungal-specific antibodies also does not consistently differentiate between previous expo-
sure and active disease.
Fungal antigen detection assays target components of the fungal cell wall that are shed during
fungal growth. The β-(1-3)-d glucan (BDG) test detects Candida, Aspergillus, Pneumocystis, and
Fusarium species in serum specimens. It has a sensitivity of 63–90 % and specificity greater than
95 %. False-positive results may occur in patients on hemodialysis and those receiving
intravenous immunoglobulin. The galactomannan (GM) assay detects Aspergillus species in
both serum and bronchoalveolar lavage (BAL) specimens. It has a sensitivity of 70–89 % and
specificity of 85–92 % in patients with hematologic malignancies [83]. BAL testing is more
sensitive than serum testing in patients with invasive pulmonary aspergillosis [84]. False-
positive results have been noted with other filamentous fungi. While the BDG assay is capable
of detecting a broad range of fungi, both serum BDG and GM assays have similar sensitivi-
ties for Aspergillus species [85].
“Empiric” antifungal coverage is administered to patients without an identified fever source.
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Two RCTs of patients with persistent febrile neutropenia showed that the addition of empiric
amphotericin B (on day 4 of fever or on day 7) to continued antibacterial regimen reduced the
frequency of IFD [86, 87]. Initiation of antifungal agents after 4–7 days of persistent fever thus
became the standard of care. Amphotericin B (AMB) use is limited by infusion reactions and
renal toxicity. Subsequent studies have therefore focused on identifying safer and equally
effective alternatives. Lipid formulations of amphotericin B (L-AMB) are as effective but less
nephrotoxic [88]. Fluconazole lacks activity against molds (Aspergillus spp.) [89, 90]. Itracona-
zole has similar efficacy as AMB but less toxicity [91]. It should be used with caution in patients
with reduced ejection fraction or heart failure. Intravenous formulation is not available in the
United States. Erratic oral bioavailability precludes its use as an empiric agent. Voriconazole
is superior to L-AMB (fewer breakthrough fungal infections). Isavuconazole is non-inferior to
voriconazole with improved tolerability and safety. Caspofungin has similar efficacy as L-
AMB (Figure 8).
Figure 8. Alternatives to empirical amphotericin B (AMB); L-AMB, lipid formulations of amphotericin B.
“Preemptive” antifungal treatment is administered only when the evidence of IFD is suggested
by positive fungal biomarker and/or high-resolution imaging (CT chest/sinus) results. In a
meta-analysis of nine published studies of high-risk patients presenting with persistent febrile
neutropenia, diagnostic-driven strategy significantly reduced antifungal use (RR 0.48, 95 % CI
0.27–0.85) and cost without increasing IFD-related mortality (RR 0.82, 95 % CI 0.36–1.87) or
overall mortality (RR 0.95, 95 % CI 0.46–1.99) [92]. Candida and Aspergillus are the most common
fungal pathogens causing invasive disease. The widespread use of azole prophylaxis has
substantially decreased the incidence of invasive candidiasis (IC) in comparison to Aspergillus
and other molds. Serum BDG test is a useful screening tool for both Candida and Aspergillus
species. The Fungitell (BDG) assay has a positive cutoff value of >80 pg/mL. Though a negative
test result does not rule out the diagnosis of IFD, a false-positive result may occur in patients
with mucositis whose gastrointestinal tract is colonized with Candida. Serum GM (cutoff optical
density index [ODI] > 0.5) is the current gold standard for detection of invasive aspergillosis
(IA). The sensitivity of this assay is significantly reduced in patients receiving anti-mold
prophylaxis. Combining BG and GM assays improves the diagnosis of IA [93].
Aspergillus DNAemia may precede the release of fungal GM into the bloodstream. However,
Aspergillus polymerase chain reaction (PCR) testing has not been widely implemented due to
a lack of standardization. A randomized trial reported that combined serum GM and Asper‐
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gillus PCR monitoring leads to an earlier diagnosis of invasive aspergillosis [94]. A meta-
analysis of thirteen studies (N = 1670) showed that the absence of serum GM and Aspergillus
PCR-positive test may obviate the need for antifungal agents with a negative predictive value
of 100 % [95].
The echinocandins (caspofungin, micafungin, and anidulafungin) are fungicidal against most
Candida spp. with similar efficacy [96–99]. Voriconazole is the treatment of choice for invasive
aspergillosis. Isavuconazole is non-inferior to voriconazole with fewer side effects [100].
The European Organization for Research and Treatment of Cancer (EORTC) is completing
accrual (N = 556) of a phase 3 prospective trial (NCT01288378) comparing empiric and
preemptive caspofungin therapy in patients with AML or MDS. The results of this study
should clarify the utility of diagnostic testing and the efficacy of preemptive strategies in
patients receiving antifungal prophylaxis with fluconazole (Figures 9 and 10).
Figure 9. Management of persistent febrile neutropenia. L-AMB, lipid formulations of amphotericin B.
Figure 10. Management of febrile neutropenia with invasive fungal disease. L-AMB, lipid formulations of amphoteri-
cin B.
4.7. Vascular catheter–related infections
Central venous catheters (Hickman or Mediport) are frequently used in patients undergoing
cancer treatment. Neutropenic patients are at increased risk for vascular catheter–related
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infections (CRI). The hub/lumen of the catheter is the major site of colonization and source of
infection. The differential time to positivity (DTP) of 120 min or more between centrally and
peripherally drawn blood cultures is indicative of catheter-related bacteremia. Common
pathogens include coagulase-negative staphylococci, S. aureus, and Candida spp.
Febrile neutropenic patients with clinical signs of CRI should receive empiric antipseudomonal
beta-lactam agent plus vancomycin. Catheter removal should be strongly considered for
tunnel or port-pocket infections; septic phlebitis; septic shock; endocarditis; bacteremia due to
S. aureus, P. aeruginosa, or Candida spp.; and persistent bloodstream infection despite ≥72 h of
therapy. Catheter removal is not required for coagulase-negative staphylococci bacteremia.
Antimicrobial therapy is modified after availability of blood culture and susceptibility results.
Antibacterial agents should be administered for a minimum of 14 days following catheter
removal and clearance of blood cultures. Prolonged treatment for 4–6 weeks is recommended
for bacteremia complicated with deep tissue infection, endocarditis, septic thrombosis, or
persistent bacteremia or fungemia occurring >72 h after catheter removal [24].
5. Refining infection control during cancer care
Preventing infection in cancer patients is a comprehensive initiative led by Centers for Disease
Control and Prevention to reduce infections in patients with cancer. PreventCancerInfec-
tions.org is a website that provides information about neutropenia, signs and symptoms of
infections, and methods to control them. Basic infection control and prevention plan is a tool
for outpatient oncology facilities that outlines infection control policies and procedures.
Standard precautions refer to the minimum measures to prevent infection including hand and
respiratory hygiene, proper use of gowns and gloves, injection safety, medication storage and
handling, and cleaning and disinfection of devices and environmental surfaces. Transmission-
based precautions supplement standard precautions when managing potentially infectious
patients. Medical providers should perform hand hygiene before and after contact with the
patients. The examination room should be cleaned and disinfected before using it for another
patient.
Home infection prevention measures include avoiding contact with sick people or sharing
personal items, keeping household surfaces clean, consuming clean and properly cooked food,
and practicing good oral, dental, and skin hygiene. Patients should be instructed to contact
their provider immediately in the event of fever, redness, swelling, or drainage from surgical
and vascular catheter sites. Annual influenza vaccination with the inactivated virus is recom-
mended for all caregivers.
High-risk patients with febrile neutropenia require hospital admission. Allogeneic HSCT
recipients should be confined in private rooms with >12 air exchanges/h and high-efficiency
particulate air filtration. Non-transplant patients do not require a private room. Household
pets, fresh flowers, and plants should not be allowed in the rooms [24]. Patients should take
daily showers, maintain good health hygiene, and eat well-cooked foods. Rectal thermometers,
enemas, suppositories, and rectal examinations should be avoided during periods of neutro-
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penia. Healthcare workers and visitors with symptomatic infections should avoid contact with
the neutropenic patient. Hospitals should conduct periodic risk assessment of multidrug-
resistant organism acquisition and transmission.
6. Conclusions
Infection is an important cause of morbidity and mortality in cancer patients. Febrile neutro-
penia is a frequent and expensive complication of myelosuppressive chemotherapy. Evidence-
based guidelines provide strong recommendations for the empiric management of initial fever
and persistent fever. The management of febrile patients receiving anti-yeast or anti-mold
prophylaxis is still evolving. The best management of recurrent fever remains unanswered.
Judicious use of antimicrobial prophylaxis is an important infection prevention strategy. Hand
hygiene, contact precautions, and disinfecting patient-care equipment remain crucial ap-
proaches for preventing the spread of infections in medical facilities. The repertoire of new
medications for the treatment of cancer is continually expanding. Physicians should be vigilant
of the immunosuppressive potential and the risk of opportunistic infections associated with
the use of these newer biologics.
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